FDA

thumbs up

How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again

Clovis Oncology Inc. (NASDAQ: CLVS) posted a massive gain of 27% to $23.03 on Tuesday, on the heels of news that the Food and Drug Administration (FDA) had granted it ...
Read Full Story »
Female patient on gurney

How Clovis Scored Big on a Milestone FDA Approval

Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food and Drug Administration (FDA) approval. Note that this is the ...
Read Full Story »
analysis

Why Bristol-Myers Failure Is a Huge Win for Merck

Shares of Bristol-Myers Squibb Co. (NYSE: BMY) took a nosedive in Friday’s session following an update in its late-stage Checkmate trial. Unfortunately the results did not reach the primary endpoint, and ...
Read Full Story »
blood cells

Theranos Death Watch Continues

Theranos CEO Elizabeth Holmes presented a new blood test system as a means to diversify beyond its earlier, failed products. Based on most accounts, many scientists who saw the presentation ...
Read Full Story »
Female patient on gurney

Is This the Turning Point Puma Biotech Investors Have Waited For?

Puma Biotechnology Inc. (NYSE: PBYI) watched its shares make a handy gain on Friday morning after the firm released updated results from its late-stage breast cancer trial. Although 2016 has been ...
Read Full Story »
Female patient on gurney

Could This Be the Turning Point for Progenics and Valeant?

Shares of Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Valeant Pharmaceuticals International Inc. (NYSE: VRX) made handy gains in the market on Wednesday following a key U.S. Food and Drug Administration (FDA) ...
Read Full Story »
Female patient on gurney

Synergy Pharmaceuticals Sinks on FDA Update

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) stumbled on Friday, and over the course of the week for that matter, despite a strong upward push in the broad markets. The company has ...
Read Full Story »
Female patient on gurney

CytRx Crumbles on Late-Stage Whiff

CytRx Corp. (NASDAQ: CYTR) absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results. The company announced the results of an analysis of its global, randomized, ...
Read Full Story »
blue eye

Shire Gains Key FDA Approval in Dry Eye Treatment

Shire PLC (NASDAQ: SHPG) made waves Tuesday morning following a key U.S. Food and Drug Administration (FDA) approval. The company announced that the FDA has approved Xiidra (lifitegrast ophthalmic solution) 5%, ...
Read Full Story »
Female patient on gurney

Ampio Crashes After Late-Stage Trial Failure

Ampio Pharmaceuticals, Inc. (NYSEMKT: AMPE) is watching its shares get cut in half on Thursday after news of a failed late-stage trial. The company announced the results of its Ampion PIVOT ...
Read Full Story »
Medicine pills

Eli Lilly Rises on Positive FDA Committee Vote

Eli Lilly and Co. (NYSE: LLY) is watching its shares make a decent gain on Wednesday following a U.S. Food and Drug Administration (FDA) vote. The FDA Advisory Committee voted ...
Read Full Story »
biotech word cloud

Why Regulus Is Tanking

Regulus Therapeutics Inc. (NASDAQ: RGLS) saw its shares cut in half early Tuesday morning following news of a clinical hold from the U.S. Food and Drug Administration (FDA). The company ...
Read Full Story »
Female patient on gurney

Could This Be a Turning Point for Fate Therapeutics?

Shares of Fate Therapeutics Inc. (NASDAQ: FATE) saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval. Looking at the stock performance in 2016, ...
Read Full Story »
local produce

Does Whole Foods Face Systemic FDA Warnings?

Whole Foods Market Inc. (NASDAQ: WFM) is under fire by federal regulators after an inspection conducted back in February. By the looks of this, it could be tough for the ...
Read Full Story »
clinical trials

Why Sarepta’s PDUFA Delay Is a Good Thing

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade. Janney Montgomery Scott has a Neutral rating on Sarepta but increased its fair value estimate to ...
Read Full Story »